Pham Quang X sold $2K of CVKD
Pham Quang X (CEO and Chairman) sold 349 shares of Cadrenal Therapeutics, Inc. (CVKD) at $4.46 on 2026-06-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This is a disclosed insider sale by the CEO/Chairman; the presence of a 10b5-1 plan generally lowers the likelihood that the trade reflects new, nonpublic negative information.
Market read
Traders may note the insider sale, but the 10b5-1 structure and small dollar amount suggest limited incremental information.
What to watch
The article does not state whether there were concurrent buys, changes in total insider ownership beyond this transaction, or any new operational/clinical catalyst.
Background
The article is an SEC Form 4 insider transaction disclosure for Cadrenal Therapeutics, Inc. (CVKD).
Ticker impact
Cadrenal Therapeutics CEO/Chairman Pham Quang X sold 349 shares in an open-market transaction under a 10b5-1 plan, disclosed via Form 4.
Likely limited near-term price impact; any reaction should be small unless accompanied by other company-specific catalysts.
The filing provides a specific sale datapoint, but it is explicitly under a pre-arranged 10b5-1 plan and involves a relatively small value (~$1.6k).
Market effects
No clear sector read-through from a single, small 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
Because the sale is 10b5-1 pre-arranged, it may reflect routine liquidity rather than negative fundamentals; traders may ignore it unless follow-on selling accelerates.
Key entities
- issuerCadrenal Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderPham Quang X
CEO and Chairman; sold 349 shares at $4.46/share under a 10b5-1 plan.
